FDA Will Accept QT/QTc Comments Through Mid-February
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is reopening the comment period for the International Conference on Harmonization QT prolongation draft guidances after a request from Wyeth. The comment period had ended in December.
You may also be interested in...
Pre-Clinical QT Prolongation Guidance Urges In Vitro, In Vivo Studies
FDA's 1draft guidance on preclinical evaluation of QT prolongation urges drug companies to initiate follow-up studies when nonclinical studies are inconsistent
QT Prolongation Draft Guidance Urges Single Clinical Trial For Evaluation
The ECG trial should be early in clinical development (but not the first study) should be carried out in healthy volunteers and include a positive control group, FDA’s draft guidance says.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.